Results 111 to 120 of about 12,013,030 (353)
Molecular Oncology, EarlyView.The cancer problem is increasing globally with projections up to the year 2050 showing unfavourable outcomes in terms of incidence and cancer‐related deaths. The main challenges are prevention, improved therapeutics resulting in increased cure rates and enhanced health‐related quality of life.
Ulrik Ringborg +43 more
wiley +1 more source
A computer architecture based on disruptive information technologies for drug management in hospitals. [PDF]
PeerJ Comput Sci, 2023 Chalmeta R +2 more
europepmc +1 more source
LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro
Molecular Oncology, EarlyView.Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix +13 more
wiley +1 more source
Development of a Drug Management Performance Application: A Needs Assessment in Indonesia. [PDF]
Healthc Inform Res, 2023 Faradiba, Satibi, Lazuardi L.
europepmc +1 more source
Patient Preference and AdherenceZhitong Zhang,1 Xiuli Bai,2 Le Hao,3 Yanli Wang2 1School of Nursing, Inner Mongolia Medical University, Hohhot, Inner Mongolia, People’s Republic of China; 2Department of Nursing, Inner Mongolia People’s Hospital, Hohhot, Inner Mongolia, People’s ...
Zhang Z, Bai X, Hao L, Wang Y
doaj
ToxicsMicroplastic and nanoplastic (MNP) particles have been observed in various human organs. However, polypropylene (PP), one of the top three most commonly detected types of MNPs in terms of quantity, is also present in injections given for the infusion ...
Jie Wang +5 more
doaj +1 more source
The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity
Molecular Oncology, EarlyView.Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli +7 more
wiley +1 more source
Drug management of autosomal dominant polycystic kidney disease. [PDF]
Aust Prescr, 2022 Theivendran T, Ramachandran A, Rangan G.
europepmc +1 more source